Preview

PDF (Published version) 147458 - an ove...pdf | Download (1MB) | Preview

Abstract

The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.

Item Type:	Article
Authors/Creators:	Shahcheraghi, SH and Ayatollahi, J and Aljabali, AAA and Shastri, M and Shukla, SD and Chellappan, DK and Jha, NK and Anand, K and Katari, NK and Mehta, M and Satija, S and Dureja, H and Mishra, V and Almutary, AG and Alnuqaydan, AM and Charbe, N and Prasher, P and Gupta, G and Dua, K and Lotfi, M and Bakshi, HA and Tambuwala, MM
Keywords:	COVID-19, COVID-19 vaccines, SARS-CoV-2
Journal or Publication Title:	Therapeutic Delivery
Publisher:	Future Science Ltd.
ISSN:	2041-5990
DOI / ID Number:	10.4155/tde-2020-0129
Copyright Information:	Copyright 2021 Murtaza Tambuwala. This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Related URLs:	UTAS Profile: Shastri, M
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page